Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Guselkumab patent expiration?Does lipitor's effectiveness decrease with high fat meals?What's the advised delay for milk post lipitor?Pramlintide approval date?Dabrafenib patent expiration?
See the DrugPatentWatch profile for vascepa
Vascepa (icosapent ethyl), a purified EPA omega-3 fatty acid used to lower triglycerides, has no documented pharmacokinetic or pharmacodynamic interactions with vitamin D supplements or deficiency states. Clinical trials, prescribing information, and drug interaction databases like Drugs.com and Lexicomp report no alerts for this combination.[1][2]
Vascepa reduces triglyceride synthesis in the liver and enhances clearance without affecting LDL cholesterol significantly. Vitamin D regulates calcium absorption, bone health, and inflammation via receptor binding. Their mechanisms do not overlap—Vascepa targets lipid metabolism, while vitamin D influences endocrine and immune pathways—reducing interaction risk.[3][4]
Patients commonly combine them without issues in REDUCE-IT trial data and real-world use. No dose adjustments needed. Monitor triglycerides and vitamin D levels routinely if prescribed for deficiency.[1][6]
Consult for personalized advice if you have liver disease, take statins, or high-dose vitamin D (>4,000 IU daily), as unrelated factors could influence monitoring. No routine interaction testing required.[2] [1]: Vascepa Prescribing Information [2]: Drugs.com - Vascepa Interactions [3]: PubMed - Icosapent Ethyl Mechanism [4]: NIH - Vitamin D Fact Sheet [5]: Journal of Clinical Endocrinology - Vitamin D and Lipids [6]: NEJM - REDUCE-IT Trial
Other Questions About Vascepa :